Company Directory / research
PrivateFor profitresearchWaltham, United States
Orionis Biosciences
Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.
- Founded
- 2015 11 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $79M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
11 years old.
Reach
Website ranked #7,788,913 in the world for traffic, about 707 visits a month.
What it does
BiotechnologyHealth CareHealth DiagnosticsMedical
Funding, as listed
$79M currency not stated
- Rounds7
- LatestSeries c, Oct 2022
- Investors8, 2 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Orionis Biosciences, field by field. Contact details are held but never shown.
The company
- Name
- Orionis Biosciences
- Type
- For profit
- Status
- Private
- Founded
- 2015
- Founders
- Nikolai Kley
- Industry
- research
- Categories
- Biotechnology, Health Care, Health Diagnostics, Medical
Where
- City
- Waltham
- Country
- United States
- Markets
- Greater Boston Area, East Coast, New England, Northeastern US
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #7,788,913
- Monthly web visits
- 707
Funding, as listed
- Total
- 79,492,454 (currency not stated)
- Rounds
- 7
- Latest round
- Series c
- Latest round date
- Oct 2022
- Investors
- 8
- Lead investors
- 2
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Orionis Biosciences may be growing as evidenced by their recent collaboration with Genentech to discover and develop molecular glue class medicines, which suggests an expansion of their research and development capabilities. Additionally, the company has initiated a Phase 1 clinical trial for ORB-011 in patients with advanced solid tumors, indicating progress in their clinical development pipeline. Furthermore, the entry of their novel immunotherapy into Phase I clinical trials, as marked by ChemDiv, demonstrates advancement in their product development and potential for future revenue streams.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in United States.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.